FDA-Drug2026-10-16Class IICHEMICAL
Pfizer Levoxyl 175 mcg tablets recalled for subpotent drug content
What this means
Pfizer is recalling specific lots of Levoxyl (levothyroxine sodium) 175 mcg tablets because stability testing found the drug potency fell below required specifications. This means some tablets may contain less active medication than labeled. The recall affects 134 bottles with lot number 24W07, expiring 11/30/2026.
- Check if your prescription bottle has lot number 24W07 and an expiration date of 11/30/2026.
- If you have this lot, contact your pharmacist or doctor before stopping or replacing your medication.
- Do not stop taking levothyroxine without medical guidance, as this can cause health problems.
The agency's original wording
Hazard
Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide and Puerto Rico
Affected count
134 1000-count bottles
Manufactured in
66 Hudson Blvd, Manhattan, New York, United States
Products
Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 1000-count bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-10
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0051-2027More Pfizer recalls
- FDA-Drug2026-10-16Pfizer Levoxyl 175 mcg tablets recalled for subpotent drug strength
- FDA-Drug2026-09-23Pfizer Dopamine HCl injection recalled for lack of sterility assurance
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.